Published: 2 January 2020
Author(s): Gianluca Rigatelli, Marco Zuin, Fabio Dell'Avvocata, Loris Roncon, Dobrin Vassilev, Nguyen Nghia
Issue: January 2020
Section: Original article

Transcatheter closure of both symptomatic atrial septal defect (ASD) and patent foramen ovale (PFO) has become a standard procedure in daily clinical practice, guaranteeing excellent technical results in terms of efficacy and safety. Although indications to closure are different between ASD and PFO, device type and shape are constructively very similar and in some case even identical between ASD and PFO populations [1]: as result, any proposed antiplatelet therapy was irrespective to the defect type and the two population can be analysed as a single one for pharmacologic purposes.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.